Company Description
OmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States.
The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics.
Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates.
The company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur that features unique structural attributes of cow antibodies for complex targets.
The company was founded in 2012 and is headquartered in Emeryville, California.
| Country | United States |
| IPO Date | n/a |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 106 |
| CEO | Matthew W. Foehr |
Contact Details
Address: 5980 Horton Street EmeryVille, California United States | |
| Website | https://www.omniab.com |
Stock Details
| Ticker Symbol | OABIW |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001846253 |
| CUSIP Number | 68218J111 |
| ISIN Number | US68218J1117 |
| Employer ID | 00-0000000 |
| SIC Code | 8731 |
Key Executives
| Name | Position |
|---|---|
| Matthew W. Foehr | President, Chief Executive Officer & Director |
| Charles S. Berkman J.D. | Chief Legal Officer & Secretary |
| Kurt A. Gustafson | Executive Vice President of Finance & Chief Financial Officer |
| Cia McCaffrey | Vice President of People & Talent |
| Donna Ventura CPA | Senior Vice President & Corporate Controller |
| Dr. Bill Harriman Ph.D. | Senior Vice President of Antibody Discovery |
| Dr. Christel Iffland Ph.D. | Senior Vice President of Antibody Technologies |
| Dr. Douglas S. Krafte Ph.D. | Senior Vice President of Ion Channels/Transporters & Icagen Ion Channel Technology Site Head |
| Marie-Cecile van de Lavoir D.V.M., Ph.D. | Senior Vice President of Technical Operations & Genetics |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 10, 2024 | 4 | Filing |
| Dec 10, 2024 | 4 | Filing |
| Dec 10, 2024 | 4 | Filing |
| Nov 26, 2024 | 4 | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | 8-K | Current Report |
| Nov 01, 2024 | 4 | Filing |
| Nov 01, 2024 | 4 | Filing |
| Aug 08, 2024 | 10-Q | Quarterly Report |